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Huay‑Cheem Tan1,2, Terrance Chua8, Mark Yan‑Yee Chan1,2, Jack Wei Chieh Tan8, 
Heerajnarain Bulluck12,13,18 & Derek J. Hausenloy2,6,14,15,16,18* 
Smoking is one of the leading risk factors for cardiovascular diseases, including ischemic heart 
disease and hypertension. However, in acute myocardial infarction (AMI) patients, smoking has been 
associated with better clinical outcomes, a phenomenon termed the “smoker’s paradox.” Given the 
known detrimental effects of smoking on the cardiovascular system, it has been proposed that the 
beneficial effect of smoking on outcomes is due to age differences between smokers and non‑smokers 
and is therefore a smoker’s pseudoparadox. The aim of this study was to evaluate the association 
between smoking status and clinical outcomes in ST‑segment elevation (STEMI) and non‑STEMI 
(NSTEMI) patients treated by percutaneous coronary intervention (PCI), using a national multi‑ethnic 
Asian registry. In unadjusted analyses, current smokers had better clinical outcomes following STEMI 
and NSTEMI. However, after adjusting for age, the protective effect of smoking was lost, confirming 
a smoker’s pseudoparadox. Interestingly, although current smokers had increased risk for recurrent 
MI within 1 year after PCI in both STEMI and NSTEMI patients, there was no increase in mortality. In 
summary, we confirm the existence of a smoker’s pseudoparadox in a multi‑ethnic Asian cohort of 
STEMI and NSTEMI patients and report increased risk of recurrent MI, but not mortality, in smokers.
Cardiovascular disease (CVD) is the leading cause of death worldwide accounting for about 30% of  deaths1. 
CVD is an imminent health threat as the number of global deaths from CVD has been rapidly increasing due 
to the aging  population2–4. Among the various CVDs, acute myocardial infarction (AMI) results in a significant 
30-day mortality of between 3 and 14%5.
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Smoking is one of the strongest risk factors for cardiovascular disease including  AMI6. However, paradoxi-
cally, a number of clinical studies have documented that smokers might have a better prognosis following AMI 
events as compared to non-smokers in both patients with ST-segment elevation (STEMI) and non-ST-segment 
elevation myocardial infarction (NSTEMI)7,8. To explain this seemingly counter-intuitive beneficial effect of 
smoking on AMI, a number of hypotheses have been proposed; (1) preconditioning of cardiomyocytes, (2) 
cellular reprograming from necrosis to  apoptosis9, and (3) reduced impact of  platelets10. Of these, the precondi-
tioning phenomenon has been most supported due to the established role of preconditioning on the regenera-
tion of  cardiomyocytes11. The size of the infarct is strongly associated with patient outcomes, such as all-cause 
mortality and hospitalization after  STEMI12. Based on this observation and the possibility that cigarette smoking 
may mimic a transient preconditioning stimulus, it has been proposed that smoking leads to a better outcome 
via preconditioning in cardiomyocytes and, therefore, decreases the size of  infarction13,14.
The results of previously published observational studies demonstrating beneficial effects of smoking and 
post-AMI outcomes have been  challenged7,8. In both of these reports, the average age of smokers was about 
9 years younger than that of non-smokers. Despite the fact that aging is one of the risk factors of AMI, the age 
difference was not adjusted in the studies. Therefore, it is still possible that the observed “protection” was pre-
sumably due to younger age of the smokers rather than smoking  itself15. The role of cigarette smoking on the 
outcomes of STEMI and NSTEMI patient remains controversial and has implications on public health. As such, 
to further clarify this issue, a national population-based multi-ethnic Asian acute myocardial infarction registry 
was used to evaluate the associations between smoking status and clinical outcomes in STEMI and NSTEMI 
patients treated by percutaneous coronary intervention.
Methods
Data collection. For this study, data from a national registry, the Singapore Myocardial Infarction Registry 
(SMIR), were utilized. The institutional review board granted an exemption for conducting this study without 
need for informed consent (SingHealth Centralised Institutional Review Board Reference No: 2016/2480) as 
this study involved analysis of a dataset without identifiers. The research was conducted in accordance with the 
Declaration of Helsinki. The SingHealth Centralised Institutional Review Board approved the research, and all 
research was performed in accordance with relevant guidelines/regulations. The SMIR collects epidemiology 
and clinical data of AMI cases diagnosed in the public and private hospitals in Singapore, in addition to certi-
fied out-of-hospital AMI  deaths16–18. Reporting of AMI cases to this registry is mandated by law in accordance 
with the National Registry of Diseases Act. The registry data included patient medical claim listings, hospital 
in-patient discharge summaries and cardiac biomarker listings from hospital laboratories. To identify the cases 
of AMI, the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 
410 was used for the data collected between 2007 and 2011. For any data that were collected from 2012 onwards, 
ICD-10 (Australian Modification) codes I21 and I22 were used to identify AMI. The AMI cases were further 
classified into STEMI and NSTEMI based on diagnosis documented by the clinicians in the medical records. The 
following criteria were used to define STEMI: (1) chest pain for 20 min, (2) significant ST-segment elevation, and 
(3) positive for cardiac biomarkers. To ensure that the data were captured in an accurate and consistent manner 
across all hospitals over the years, annual internal audit was performed. Among the STEMI and NSTEMI cases 
in January 2007 to December 2015, information on the patients who received PCI was extracted and utilized for 
analysis. Only patients who received PCI were included as the patients with a Type 1 MI were the focus of this 
study.
Clinical outcomes. The primary clinical outcome of this study was all-cause mortality at 1-year post-pres-
entation. Mortality data were obtained from the Death Registry of Ministry of Home Affairs and were merged 
with the SMIR data. Secondary outcomes included all-cause mortality at 30 days post-presentation, and the 
first episode of MI occurring within 1  year after the index PCI. The analyses were stratified by the type of 
AMI (STEMI and NSTEMI) and patients were compared based on their smoking status (never smoked, former 
smoker, and current smoker). Smoking data were self-reported by the patients or their family based on docu-
mentation in the medical records.
Statistical analysis. Categorical variables were expressed as frequency and percentages, while continu-
ous variables were expressed as median and interquartile range. Missing data were excluded from the analyses 
through case deletion without imputation to maintain data in its original form. Univariable and multivariable 
cox regression were performed to determine the hazards ratios (HR) of having the primary and secondary 
outcomes. Specifically for the secondary outcome of recurrent AMI, competing risk from non-AMI deaths was 
adjusted using the Fine-Gray proportional hazards  model19.
This study did not require informed consent according to the exemption granted by the institutional review 
board as this was a study using deidentified data (SingHealth CIRB Reference No: 2016/2480). This study followed 
the principles of the Declaration of Helsinki. The statistician of the study had access to anonymized individual 
data, while the other co-authors had access to the analyzed aggregated data. All analyses were done using Stata 
SE Version 13 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP). All 
statistical tests were 2-tailed and results were deemed to be statistically significant if p < 0.05.
Results
Study population. A total of 21,261 AMI patients (12,307 STEMI and 8,954 NSTEMI) who received PCI 
from January 2007 to December 2015 were included in this study (Fig. 1). The SMIR population was multi-ethnic 
with about three-fifths being Chinese, one-fifth Malays and one-fifth Indian (Tables 1 and 2). The STEMI group 
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comprised 4549 (37%) never smoked, 1703 (14%) former smokers, and 6055 (49%) current smokers (Table 1). 
The median age of patients who never smoked or were former smokers were similar, but the median age of 
current smokers was significantly less by 8 years. The NSTEMI group comprised 3902 (44%) never smoked, 
1766 (20%) former smokers, and 3286 (37%) current smokers (Table 2). The median age of current smokers 
with NSTEMI patients was about 9 years less than the never smoked and former smokers. For both STEMI 
and NSTEMI, former and current smokers were predominantly male (> 90%), when compared to patients who 
have never smoked (50–60%) (Tables 1 and 2). The female patients with STEMI had a worse 1-year-mortality 
(HR 1.33, 95% CI 1.05–1.69), suggesting that gender was a potential confounding factor. Therefore, gender was 
included for adjustment when the multivariate regression was performed.
Clinical outcomes. In the STEMI group, the unadjusted HRs for death within 1 year were significantly 
lower for current smokers (HR 0.50), when compared to never smokers (Table 3). For death within 30 days, 
the unadjusted HRs were significantly lower in both former (HR 0.68) and current (HR 0.50) smokers, when 
compared to never smokers (Table 3). The Kaplan Meier analysis also displayed the beneficial effect of smoking 
on the three primary outcomes in STEMI and NSTEMI patients (Supplementary Figure S1). However, after 
adjustment for potential confounders, this protective effect was no longer observed (Table 3). Similar 30-day and 
1-year mortality results were observed when we stratified the analysis by ethnicity (Table 3). Notably, although 
the unadjusted HRs for recurrent MI within 1 year did not differ significantly according to smoking status, the 
adjusted HR for current smokers (HR 1.39) was significantly higher than never smokers, especially among Chi-
nese patients, suggesting that current smokers have increased risk of recurrent MI following STEMI.
Similar findings were observed in the NSTEMI group, with unadjusted HR for death significantly lower for 
current smokers at 30 days (HR 0.32) and at 1 year (HR 0.45) (Table 4). After adjusting for potential confounders, 
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Figure 1.  Flowchart of data inclusion. 74,807 patients were registered in the Singapore Myocardial Infarction 
Registry (SMIR). 6920 patients were excluded from the data analysis as the type of their acute coronary 
syndrome (ACS) was unclear. This exclusion left only ST elevation myocardial infarction (STEMI) and Non-
STEMI (NSTEMI) in the dataset. Those who did not undergo percutaneous coronary intervention (PCI) or did 
not have smoking data were excluded from the data analysis. The patients were then further divided into the 
details of their smoking status.
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we stratified the analysis by ethnicity. Notably, the unadjusted HRs for recurrent MI within 1 year were mixed, 
being higher for former smokers (HR 1.39), but lower for current smokers (HR 0.68), when compared to never 
smokers. After adjusting for potential confounders, the adjusted HRs remained significantly higher for both 
former smokers (HR 1.45) and current smokers (HR 1.46), especially among Chinese patients, suggesting that 
current smokers have increased risk of recurrent MI following NSTEMI.
Discussion
In this national registry-based study of a multi-ethnic cohort of AMI patients treated by PCI, we found that 
former and current smokers had a decreased unadjusted HR for both 30-day and 1-year mortality, when com-
pared to never smokers. However, this protective effect of smoking was not present after adjustment of potential 
confounding factors, suggesting the existence of a smokers’ pseudoparadox on mortality for both STEMI and 
NSTEMI. We found an increased adjusted HR for recurrent MI within 1 year among current smokers in the 
STEMI group and the Chinese STEMI sub-group. Similarly, we found that the adjusted risk for recurrent MI 
within 1 year were increased among both former and current smokers in the NSTEMI group.
The smoker’s paradox was first described in 1968 by Weinblatt et al. as an unexpected result because the 
smokers had a lower 1 month mortality after their MI events as compared to non-smokers in the  report20. This 
paradoxical result was observed in another independent study by Tamsin Lisa et al. where the smokers had a 
lower prevalence for AMI and other CVDs, such as hypertension, congestive heart failure and angina pectoris 
when logistic regression was  performed21. In this paper, the authors noted that smokers were about 10 years 
younger than the non-smokers and this paradoxical result was presumably due to the age difference, given that 
age is one of the most important factors for developing CVDs and predisposes to AMI events via generation of 
reactive oxygen species (ROS), cellular senescence, and epigenetic  changes22–24.
Many of the former studies which attempted to elucidate the association of smoking with clinical outcomes of 
AMI had intrinsic limitations. For example, one of the earlier studies using data from three hospitals reported the 
protective effect of smoking on the outcomes of acute  STEMI8. However, this study did not have age adjustment 
despite the significant difference in age between smokers and non-smokers which makes data interpretation 
difficult. Similarly, in another study where national Malay data were utilized, the study reported a positive cor-
relation between smoking and better outcomes for both STEMI and NSTEMI  patients7. This paper was one of 
Table 1.  Demographic and clinical characteristics of STEMI patients by smoking status. *AMI acute 
myocardial infarction, BMI body mass index, CABG coronary artery bypass surgery, CPR cardiopulmonary 
resuscitation, ED emergency department, IQR interquartile range, PCI percutaneous coronary intervention, 
STEMI ST-elevation myocardial infarction.
Never smoker (n = 4549) Former smoker (n = 1703) Current smoker (n = 6055) p-value
Age in years, median (IQR) 61.3 (53.8–70.8) 61.1 (53.2–70.3) 54.4 (48.0–61.1)  < 0.001
Male, n (%) 2966 (65.2) 1633 (95.9) 5876 (97.0)  < 0.001
Ethnicity, n (%)
Chinese 3057 (67.2) 1057 (62.0) 3500 (57.8)
 < 0.001
Malay 647 (14.2) 371 (21.8) 1453 (24.0)
Indian 778 (17.1) 235 (13.8) 997 (16.5)
Others 67 (1.5) 40 (2.4) 105 (1.7)
History of diabetes, n (%) 1573 (34.6) 567 (33.3) 1316 (21.7)  < 0.001
History of hypertension, n (%) 2867 (63.0) 1042 (61.3) 2491 (41.2)  < 0.001
History of hyperlipidemia, n (%) 2341 (51.5) 948 (55.7) 2331 (38.5)  < 0.001
History of AMI/CABG/PCI, n (%) 587 (12.9) 410 (24.1) 846 (14.0)  < 0.001
BMI in kg/m2, median (IQR) 24.5 (22.3–27.2) 24.9 (22.6–27.4) 24.5 (22.3–27.3) 0.035
Killip class on admission, n (%)
I 3712 (81.5) 1426 (83.8) 5109 (84.4)
 < 0.001
II 217 (4.8) 89 (5.2) 289 (4.8)
III 203 (4.5) 70 (4.1) 182 (3.0)
IV 416 (9.2) 117 (6.9) 473 (7.8)
CPR in ambulance/ED, n (%) 198 (4.4) 49 (2.9) 199 (3.3) 0.003
Serum creatinine in 10 µmol on admis-
sion, median (IQR) 9.0 (7.4–11.2) 9.6 (8.2–11.6) 8.9 (7.7–10.4)  < 0.001
Haemoglobin in g/dL on admission, 
median (IQR) 14.0 (12.7–15.2) 14.5 (13.3–15.4) 15.1 (14.1–16.1)  < 0.001
Left ventricular ejection fraction < 50%, 
n (%) 2629 (62.4) 1030 (64.4) 3384 (59.9) 0.001
Anterior infarct, n (%) 2300 (50.6) 814 (47.8) 3048 (50.3) 0.127
Symptom-to-balloon time in minutes, 
median (IQR) 193 (125–330) 196 (122–322) 180 (120–301)  < 0.001
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the few studies which utilized the national dataset and reported both STEMI and NSTEMI separately. However, 
this study again did not include adjustment for age even though there was about 9 years of difference in age 
between smokers and non-smokers, suggesting that the lack of age adjustment could possibly impact the data 
interpretation. Therefore, the abovementioned epidemiological studies which demonstrated the protective asso-
ciation of smoking with the outcomes of AMI may be confounded by the lack of statistical adjustment for age.
Two recent papers have reported the detrimental effect of smoking on the AMI outcomes. In the national 
dataset of Chinese cohort, Gao et al. found that without the proper adjustments for age and the number of 
cigarettes smoked, the smoking history was associated with a better outcome in the MI  patients25. However, 
when the number of cigarettes smoked and age are considered, the same dataset showed a significantly negative 
correlation of smoking with clinical outcomes in the MI patients. Similarly, independent groups reported that 
smoking was associated with an increased risk of all-cause mortality and heart failure from meta-analysis of PCI 
 trials26,27. However, these two studies had some limitations as the former study did not subclassify AMI patients 
into STEMI and NSTEMI and was conducted only in patients with Chinese ethnicity. Similarly, the latter study 
analyzed STEMI patients who participated in clinical trials, suggesting that the patient population might not be 
generalizable. Our present report contributes further to the field by elucidating the detrimental effect of smok-
ing on clinical outcomes of multi-ethnic STEMI and NSTEMI patients as our study utilized data of a national 
registry with appropriate statistical adjustment for potential confounders.
In our dataset, it was consistently observed that both STEMI and NSTEMI smokers were at higher risk of 
recurrent MI within 1 year. This result is consistent with the former reports by Redfors and Gao et al.as they 
also reported an increased risk of recurrent MI by  smoking25,27. Interestingly, despite the increase in recurrent 
MI, an increased all-cause mortality was not observed in our data analysis. This was an unexpected result as 
other groups observed both increased recurrent MI and all-cause  mortality25 and the recurrent MI is one of the 
strongest predictors for an increased all-cause  morality28,29. This phenomenon could be due to other factors, such 
as advances in the health care system or the short travel time between the patients’ houses and the hospitals in 
Singapore due to urbanization which would lead to better  mortality30–34. Another interesting result we found 
was that the former Malay smokers had a better clinical outcome in terms of death within 30 days after NSTEMI 
events with a hazard ratio of 0.30. This result may indicate that for this specific group, there were confounding 
factors other than age.
The detrimental association between smoking status and the clinical outcomes was observed in the overall 
and Chinese group for both STEMI and NSTEMI, but not in the Malay and Indian groups (Tables 3 and 4). This 
result suggests that the differential effect of smoking on the prognosis of STEMI and NSTEMI may be influenced 
by ethnicity. Similarly, other groups previously reported that the risk of smoking on AMI events was dependent 
Table 2.  Demographic and clinical characteristics of NSTEMI patients by smoking status. *AMI acute 
myocardial infarction, BMI body mass index, CABG coronary artery bypass surgery, CPR cardiopulmonary 
resuscitation, ED emergency department, IQR interquartile range, NSTEMI non ST-elevation myocardial 
infarction, PCI percutaneous coronary intervention.
Never smoker (n = 3902) Former smoker (n = 1766) Current smoker (n = 3286) p-value
Age in years, median (IQR) 63.5 (55.7–72.6) 63.6 (55.9–72.5) 54.9 (48.8–62.2)  < 0.001
Male, n (%) 2134 (54.7) 1658 (93.9) 3150 (95.9)  < 0.001
Ethnicity, n (%)
Chinese 2567 (65.7) 1107 (62.7) 1896 (57.7)
 < 0.001
Malay 568 (14.6) 339 (19.2) 733 (22.3)
Indian 695 (17.8) 293 (16.6) 603 (18.4)
Others 72 (1.9) 27 (1.5) 54 (1.6)
History of diabetes, n (%) 1828 (46.9) 771 (43.7) 895 (27.3)  < 0.001
History of hypertension, n (%) 2997 (76.8) 1344 (76.1) 1724 (52.5)  < 0.001
History of hyperlipidemia, n (%) 2676 (68.6) 1294 (73.4) 1802 (54.8)  < 0.001
History of AMI/CABG/PCI, n (%) 1163 (29.8) 836 (47.3) 877 (26.7)  < 0.001
BMI in kg/m2, median (IQR) 24.9 (22.5–28.0) 24.8 (22.4–27.5) 25.1 (22.8–27.9) 0.031
Killip class on admission, n (%)
I 3171 (81.2) 1380 (78.2) 2924 (89.0)
 < 0.001
II 431 (11.1) 221 (12.5) 210 (6.4)
III 256 (6.6) 142 (8.1) 112 (3.4)
IV 43 (1.1) 22 (1.3) 40 (1.2)
CPR in ambulance/ED, n (%) 25 (0.6) 10 (0.6) 15 (0.5) 0.579
Serum creatinine in 10 µmol on admis-
sion, median (IQR) 8.6 (7.1–11.3) 9.5 (7.9–12.4) 8.4 (7.2–9.7)  < 0.001
Haemoglobin in g/dL on admission, 
median (IQR) 13.3 (11.8–14.6) 13.9 (12.4–15.0) 14.8 (13.8–15.7)  < 0.001
Left ventricular ejection fraction < 50%, 
n (%) 1226 (39.0) 671 (47.5) 970 (36.2)  < 0.001
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on the types of small nucleotide polymorphism (SNP) on certain genes, such as Paraoxonase (PON1) and 
 rs112260835,36. In other words, these SNPs may determine whether smoking increases the susceptibility of subjects 
to AMI. The SNPs that are be associated with the worse prognosis by smoking in our cohort and the mechanisms 
by which smoking interacts with these SNPs need to be experimentally identified and validated in the future.
There is indirect evidence suggesting the detrimental role of smoking on AMI. For example, cases of AMI sig-
nificantly decreased after the introduction of national smoking bans in multiple countries, suggesting that smok-
ing increases the risk of  AMI37–39. Moreover, the percentage of smokers among AMI patients was significantly 
greater as compared to non-AMI  patients40. Considering the fact that cigarette smoking is attributable to 15% 
of the CVD cases and  mortality41 and increases the risk of MI, smoking should be strictly avoided. Additionally, 
there are still unanswered questions on whether second-hand smoking or cigarette alternatives like e-cigarettes 
also lead to poorer outcomes in MI patients.
A limitation of the study is that the SMIR database does not contain information on the duration of smoking 
and the number of cigarettes the smokers consume. Additionally, the SMIR does not include the information 
on how long it has been after the former smokers quit their smoking behavior. For that reason, patients who 
identified as former smokers were classified as such unlike the WHO definition which requires 12 months of 
cessation to qualify one as a former  smoker42. Hence, the results from our study may not be directly comparable 
with other studies due to the different definition. Furthermore, due to the lack of information on the number of 
cigarettes smoked, we could not examine for the presence of any potential dose–response relationship between 
smoking and outcomes.
Conclusion
In summary, we found that smokers seemingly had better clinical outcomes (30-day and 1-year mortalities) 
after STEMI or NSTEMI. However, upon adjustment, the seemingly beneficial effects of smoking on mortality 
disappeared and the risk of recurrent MI within 1-year was significant higher in STEMI and NSTEMI smokers, 
confirming the presence of a smokers’ pseudoparadox for mortality. This data demonstrates that the previously 
reported protective effect of smoking was actually pseudo-protective and smoking worsens clinical outcomes in 
both STEMI and NSTEMI patients.
Table 3.  Risk of death within 30 days, death within 1 year and recurrent MI within 1 year among former 
and current smokers compared to never smokers in STEMI patients. *Adjusted for race, age, gender, history 
of diabetes, history of hypertension, history of hyperlipidemia, history of AMI/CABG/PCI, body mass 
index, Killip class on admission, CPR in ambulance/ED, anterior infarct, serum creatinine on admission, 
haemoglobin on admission, symptom-to-balloon time, inpatient left ventricular ejection fraction. **AMI 
acute myocardial infarction, CABG coronary artery bypass surgery, CPR cardiopulmonary resuscitation, 
ED emergency department, MI myocardial infarction, PCI percutaneous coronary intervention, STEMI 
ST-elevation myocardial infarction.
Death within 30 days Death within 1 year Recurrent MI within 1 year
Unadjusted HR (95% 
CI)
Adjusted HR* (95% 
CI)
Unadjusted HR (95% 
CI)
Adjusted HR* (95% 
CI)
Unadjusted HR (95% 
CI)
Adjusted HR* (95%  
CI)
Overall
Never smoker 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Former smoker 0.68 (0.54–0.86) 0.86 (0.62–1.20) 0.87 (0.73–1.04) 1.19 (0.94–1.52) 1.07 (0.82–1.41) 1.21 (0.87–1.68)
Current smoker 0.50 (0.43–0.59) 0.84 (0.64–1.10) 0.50 (0.44–0.57) 1.00 (0.80–1.24) 1.01 (0.84–1.23) 1.39 (1.06–1.81)
P interaction between 
race and smoking 
status
0.388 0.474 0.152 0.386  < 0.001  < 0.001
Chinese
Never smoker 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Former smoker 0.79 (0.60–1.04) 1.01 (0.68–1.50) 0.95 (0.76–1.18) 1.23 (0.92–1.64) 1.16 (0.80–1.69) 1.22 (0.78–1.90)
Current smoker 0.54 (0.44–0.67) 0.90 (0.64–1.25) 0.56 (0.47–0.66) 1.09 (0.84–1.42) 1.16 (0.89–1.52) 1.57 (1.09–2.27)
Malay
Never smoker 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Former smoker 0.40 (0.23–0.71) 0.46 (0.20–1.06) 0.59 (0.40–0.86) 1.08 (0.62–1.87) 0.95 (0.56–1.62) 1.23 (0.63–2.40)
Current smoker 0.41 (0.29–0.59) 0.55 (0.29–1.05) 0.35 (0.26–0.47) 0.74 (0.44–1.24) 0.72 (0.48–1.08) 1.02 (0.61–1.71)
Indian
Never smoker 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Former smoker 0.76 (0.40–1.42) 1.12 (0.38–3.28) 0.95 (0.58–1.56) 1.40 (0.67–2.95) 1.01 (0.56–1.84) 1.13 (0.51–2.49)
Current smoker 0.44 (0.28–0.69) 1.40 (0.61–3.21) 0.47 (0.32–0.69) 1.17 (0.61–2.22) 0.95 (0.64–1.40) 1.37 (0.75–2.49)
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